Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $15.05M fell 9.5% year over year, behind the +45.0% change in trailing-twelve-month revenue. Sequentially, it fell 34.6% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 13 analysts of $43.49M (-35.7%) for the fiscal year ending Dec 2026, a slowdown from the +16.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $15.05M-34.6% QoQ
- Last fiscal yearDec 2025
- $67.67M+16.9% YoY
- LTMMar 2026
- $66.09M+45.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.5% | -8.9% | +0.6 pp |
| 1 year | +16.9% | -35.7% | -52.7 pp |
| 3-year CAGR | +9.1% | +73.2% | +64.1 pp |
| 5-year CAGR | +92.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 67.67M USD
- Year-over-year change
- +16.9%
- 4-year CAGR
- +19.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.67M | +16.9% |
| FY2024 | 2024-12-31 | 57.88M | +59.6% |
| FY2023 | 2023-12-31 | 36.28M | -30.4% |
| FY2022 | 2022-12-31 | 52.12M | +57.7% |
| FY2021 | 2021-12-31 | 33.05M | — |
Revenue vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 revenue of $66.09M is the 4th highest of the 10 companies compared; the peer median is $25.17M.
- Its year-over-year change of +45.0% is the 4th highest of 8, against a peer median of +13.0%.
- Over three fiscal years its annual growth of +9.1% compares with a peer median of +27.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $156.04M | +158.9% | +31.9% | |
| LTM Jun 2026 | $85.72M | +1875.0% | -28.9% | |
| LTM Mar 2026 | $79.76M | +131.1% | +72.3% | |
| LTM Mar 2026 | $66.09M | +45.0% | +9.1% | |
| LTM Mar 2026 | $38.69M | +8.0% | +27.1% | |
| LTM Sep 2026 | $25.17M | -33.1% | +100.4% | |
| LTM Mar 2026 | $18.09M | -10.4% | -46.7% | |
| LTM Mar 2026 | $11.2M | +13.0% | -7.0% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding NTLA) | $25.17M | +13.0% | +27.1% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.